Aducanumab for Alzheimer's disease - too many unanswered questions.
作者信息
Phizackerley David
机构信息
DTB, BMJ Journals, London, UK
出版信息
Drug Ther Bull. 2021 Sep;59(9):130. doi: 10.1136/dtb.2021.000043. Epub 2021 Jul 20.
PMID:34285129
Abstract
摘要
相似文献
1
Aducanumab for Alzheimer's disease - too many unanswered questions.用于治疗阿尔茨海默病的阿杜卡努单抗——问题太多，尚无答案。
Drug Ther Bull. 2021 Sep;59(9):130. doi: 10.1136/dtb.2021.000043. Epub 2021 Jul 20.
2
Aducanumab (Aduhelm) for Alzheimer's disease.用于治疗阿尔茨海默病的阿杜卡努单抗（阿杜海姆）
Med Lett Drugs Ther. 2021 Jul 12;63(1628):105-106.
3
Aducanumab for Alzheimer's disease?阿杜卡奴单抗治疗阿尔茨海默病？
BMJ. 2021 Jul 5;374:n1682. doi: 10.1136/bmj.n1682.
4
[Aducanumab approval for Alzheimer's disease in the USA: the surrender of science].[美国批准阿杜卡单抗用于治疗阿尔茨海默病：科学的屈服]
Rev Neurol. 2021 Oct 16;73(8):296-297. doi: 10.33588/rn.7308.2021378.
5
Aducanumab: The first targeted Alzheimer's therapy.阿杜卡努单抗：首款靶向阿尔茨海默病疗法。
Drug Discov Ther. 2021;15(3):166-168. doi: 10.5582/ddt.2021.01061.
6
The FDA Approves Aducanumab for Alzheimer's Disease, Raising Important Scientific Questions1.美国食品药品监督管理局批准阿杜卡单抗用于治疗阿尔茨海默病，引发了重要的科学问题1。
J Alzheimers Dis. 2021;82(3):881-882. doi: 10.3233/JAD-210736.
7
How the US Food and Drug Administration's approval of aducanumab for Alzheimer's disease has implication for oncology and beyond.美国食品药品监督管理局批准阿杜卡努单抗用于治疗阿尔茨海默病对肿瘤学及其他领域有何影响。
Eur J Cancer. 2021 Nov;157:68-70. doi: 10.1016/j.ejca.2021.08.012. Epub 2021 Sep 4.
8
Aducanumab for Alzheimer's disease: expediting approval and delaying science.用于治疗阿尔茨海默病的阿杜卡努单抗：加速批准与延缓科学进程
BMJ Evid Based Med. 2021 Oct;26(5):214-215. doi: 10.1136/bmjebm-2021-111765. Epub 2021 Jul 14.
9
Alzheimer's disease: the controversial approval of Aducanumab.阿尔茨海默病：阿杜卡单抗颇具争议的获批情况。
Neurol Sci. 2021 Aug;42(8):3069-3070. doi: 10.1007/s10072-021-05497-4. Epub 2021 Jul 29.
10
An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.加速批准的合理应用——阿杜卡单抗用于阿尔茨海默病
N Engl J Med. 2021 Aug 26;385(9):856-857. doi: 10.1056/NEJMc2111960. Epub 2021 Jul 28.
Zotero 插件